Inogen Announces Launch of Inogen Connect

Download as PDF

GOLETA, Calif.--(BUSINESS WIRE)-- Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the commercial launch of Inogen Connect.

The Company has launched Inogen Connect, a new wireless connectivity platform for the Inogen One G4, through its direct-to-consumer channel. The Company still expects to launch Inogen Connect in the domestic business-to-business channel for the Inogen One G4 in the first quarter of 2019.

Inogen Connect is a connectivity platform that consists of a front-end mobile application for use by oxygen therapy users and a back-end database portal for use by homecare providers. The Inogen Connect app is compatible with Apple and Android platforms and includes patient features such as oxygen purity status, battery run time, product support functions, notification alerts, and remote software updates. The Company believes features of the back-end database portal such as remote troubleshooting, equipment health checks, and a location tracker will drive operational efficiencies for home oxygen providers and lower the total cost of serving oxygen therapy patients.

Additional information on Inogen Connect can be found here: www.inogen.com/inogenconnect

Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit http://investor.inogen.com/.

About Inogen

Inogen is innovation in oxygen therapy. We are a medical technology company that develops, manufactures and markets innovative oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

For more information, please visit www.inogen.com.

Cautionary Note Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding expectations for the launch of Inogen Connect in the domestic business-to-business channel, and expectations that Inogen Connect will help drive operational efficiencies and lower the total cost of serving oxygen therapy patients. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks related to interruptions or delays in the supply of components or materials for, or manufacturing of, its products; risks relating to market acceptance of its products; and competition. In addition, Inogen's business is subject to numerous additional risks and uncertainties, including, among others, risks relating to the possibility that Inogen will not realize anticipated revenue; the possible loss of key employees, customers, or suppliers; its sales, marketing and distribution capabilities; its planned sales, marketing, and research and development activities; intellectual property risks if Inogen is unable to secure and maintain patent or other intellectual property protection for the intellectual property used in its products; seasonal variations; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting Inogen’s business operating results are contained in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Inogen disclaims any obligation to update these forward-looking statements except as may be required by law.

Investor Relations Contact:
Matt Bacso, CFA
805-879-8205

Media Contact:
Byron Myers
805-562-0503

Source: Inogen, Inc.

Released December 18, 2018